Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Liverpool Chirochem

Request full access

Specialist in chiral molecules for pharmaceutical research

Liverpool, United KingdomFounded 2014Biotech & Life Sciences

About Liverpool Chirochem

Liverpool ChiroChem (LCC) is a chemical technology company that specializes in producing chiral small molecules for the pharmaceutical and biotechnology research and development sectors. The company's products serve as building blocks, fragments, and screening compounds for drug discovery.

LCC was founded in 2014 as a spin-out from the University of Liverpool's Department of Chemistry. The founders include Professor Jianliang Xiao and his two former PhD students, Dr. Jianjun Wu and Dr. Paul Colbon, who now serves as the company's CEO, along with Dr. Jiwu Ruan, a postdoctoral researcher from Xiao's group. Paul Colbon graduated from the University of Liverpool with an MChem and a PhD, and previously worked at AstraZeneca and Redx Pharma. The company was established based on patented catalytic methods developed at the university that allow for simpler, lower-cost production of chiral compounds.

The company's primary clients are multinational pharmaceutical companies, contract research organizations (CROs), and specialist biotech firms across the United States, Europe, and Asia. Revenue is generated through the sale of its proprietary chemical compounds and custom synthesis services. A key technology is its Parallel Automated Chiral Engine (PACE), which integrates AI software and automation to design and synthesize novel chiral molecules. This platform has produced a vast collection of chiral building blocks and a proprietary virtual library of over one billion compounds.

In June 2025, following a period of administration for its entity LCC Therapeutics, Liverpool ChiroChem was acquired by XtalPi, a life sciences R&D platform that utilizes quantum physics, AI, and robotics. The acquisition, described as a strategic merger, is intended to enhance XtalPi's capabilities in exploring and synthesizing new chemical spaces for various applications, including pharmaceuticals, materials, and agriculture. Dr. Paul Colbon has remained as CEO to guide the collaboration between the two teams.

Source: Dealroom company data

Liverpool Chirochem in the Liverpool ecosystem

Live from Dealroom

The Liverpool Chirochem office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Praetura Ventures
  • Northern Powerhouse Investment Fund
  • Deepbridge Capital

Series B and later6 investors entered at this stage

  • Maven Capital Partners
  • Future Fund
  • Cheshire and Warrington Local Enterprise Partnership
  • Greater Manchester Combined Authority
  • Bruntwood
  • Gmctrading
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · Liverpool HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Liverpool Chirochem on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Liverpool Chirochem on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.